KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Treasury Shares (2017 - 2026)

NovoCure's Treasury Shares history spans 10 years, with the latest figure at $12.6 million for Q1 2026.

  • On a quarterly basis, Treasury Shares fell 9.21% to $12.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.6 million, a 9.21% decrease, with the full-year FY2025 number at $13.1 million, up 8.85% from a year prior.
  • Treasury Shares hit $12.6 million in Q1 2026 for NovoCure, down from $13.1 million in the prior quarter.
  • Over the last five years, Treasury Shares for NVCR hit a ceiling of $13.9 million in Q1 2025 and a floor of $5.0 million in Q1 2022.
  • Historically, Treasury Shares has averaged $9.6 million across 5 years, with a median of $12.1 million in 2024.
  • Biggest five-year swings in Treasury Shares: skyrocketed 142.87% in 2024 and later fell 9.21% in 2026.
  • Tracing NVCR's Treasury Shares over 5 years: stood at $5.4 million in 2022, then grew by 8.1% to $5.8 million in 2023, then surged by 107.58% to $12.1 million in 2024, then rose by 8.85% to $13.1 million in 2025, then decreased by 3.86% to $12.6 million in 2026.
  • Business Quant data shows Treasury Shares for NVCR at $12.6 million in Q1 2026, $13.1 million in Q4 2025, and $13.6 million in Q3 2025.